Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed Papers
Activation of Invariant NKT Cells in Early Phase of Experimental Autoimmune Encephalomyelitis Results in Differentiation of Ly6Chi Inflammatory Monocyte to M2 Macrophages and Improved Outcome.
The VZV/IE63-specific T cell response prevents herpes zoster in fingolimod-treated patients.
Differences in Diffusion Tensor Imaging-Derived Metrics in the Corpus Callosum of Patients With Multiple Sclerosis Without and With Gadolinium-Enhancing Cerebral Lesions.
Recommendations on diagnosis and treatment of depression in patients with multiple sclerosis.
Back on the scent: the olfactory system in CNS demyelinating diseases.
Fingolimod for the Treatment of Intracerebral Hemorrhage: A 2-Arm Proof-of-Concept Study.
Central Nervous System and its Disease Models on a Chip.
TRPM4 cation channel mediates axonal and neuronal degeneration in experimental autoimmune encephalomyelitis and multiple sclerosis.
MSQoL-54 predicts change in fatigue after inpatient rehabilitation for people with multiple sclerosis.
Health-related quality of life and disease-modifying treatment behaviour in relapsing-remitting multiple sclerosis - a multicentre cohort study.
Multiple sclerosis shrinks intralesional, and enlarges extralesional, brain parenchymal veins.
Expansion of oligodendrocyte progenitor cells following SIRT1 inactivation in the adult brain.
Neuromyelitis optica: clinical manifestations and neuroimaging features.
Acute reversible periependymal ventricular enhancement in neuromyelitis optica.
Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzyme.
Please mind the gap: axonal transport deficits in multiple sclerosis neurodegeneration.
FTY720 is neuroprotective after cuprizone-induced central nervous system demyelination.
Natalizumab-induced autoimmune hepatitis in a patient with multiple sclerosis.
Reversible cerebral vasoconstriction syndrome associated with fingolimod treatment in relapsing-remitting multiple sclerosis three months after childbirth.
Microglia: Architects of the Developing Nervous System.
Prevalence of human herpesvirus U94/REP antibodies and DNA in Tunisian multiple sclerosis patients.
B cells populating the multiple sclerosis brain mature in the draining cervical lymph nodes.
Modelling and Prediction of 25-Hydroxyvitamin D Levels in Norwegian Relapsing-Remitting Multiple Sclerosis Patients.
Re-evaluation of the risk for major adverse cardiovascular events in patients treated with anti-IL-12/23 biological agents for chronic plaque psoriasis: a meta-analysis of randomized controlled trials.
Comprehensive Immunophenotyping of Cerebrospinal Fluid Cells in Patients with Neuroimmunological Diseases.
Pages
« first
‹ previous
…
158
159
160
161
162
163
164
165
166
…
next ›
last »